Sattva Sukun Lifecare Ltd. (SATTVASUKU) — Tipsheet

Sattva Sukun's profit plummets 92% after rights issue

Tipsheet Editorial — Thu, 04 Jun 2026 20:45:41 GMT

Annual net profit fell to ₹21.17 lakhs from ₹248.94 lakhs. The company confirms the ₹19.16 crore raised in its rights issue was spent as planned.

What’s new

Sattva Sukun's consolidated net profit fell 92% year-over-year to ₹21.17 lakhs.
The company states the ₹19.16 crore from its rights issue was used as intended.
The annual results carry an unmodified auditor's report.

Why it matters

A 92% profit collapse is severe for any company. For a nano-cap that just raised ₹19.16 crore from public shareholders, it raises immediate questions about the quality of earnings the new capital is meant to scale. The clean audit opinion and no-deviation confirmation on funds are procedural checkboxes, not comforts.

What we’re watching

How management explains the profitability collapse in its commentary.
Quarterly progression to see if the decline is front-loaded or structural.
Any changes to capital allocation plans post the rights issue.

The full read

Sattva Sukun just posted a terrible set of annual numbers. Consolidated net profit fell 92% to ₹21.17 lakhs, from ₹248.94 lakhs the year before. This comes right after the company completed a ₹19.16 crore rights issue, and the filing confirms that money was spent as planned. The audit is clean. The compliance boxes are ticked. But a 92% profit collapse is the real story here. For a nano-cap that just tapped public markets, the core question is how the fresh capital generates value when underlying profitability has cratered. The no-deviation statement on funds is procedural. The profit number is operational. They tell very different stories.

Primary source: BSE · NSE

Sattva Sukun reports FY26; rights-issue proceeds spent as planned

Tipsheet Editorial — Thu, 04 Jun 2026 20:36:28 GMT

Audited results for Q4 and FY26 are in. The auditor gave a clean opinion, and the company confirmed it used its ₹19.16 crore rights-issue money with no deviations.

What’s new

Audited standalone and consolidated results for the quarter and year ended March 31, 2026, are approved.
Auditor's report is unmodified; no qualifications or emphasis-of-matter paragraphs.
Deviation statement confirms full use of ₹19.16 crore rights-issue proceeds.

Why it matters

This is a routine annual compliance filing for a nano-cap. The clean audit and deviation clearance are table stakes, but they do remove a potential governance overhang. The filing contains no new guidance or strategic update to move the stock on its own.

What we’re watching

How the market digests the updated financials relative to the prior board intimation.
Any movement in promoter holding or significant balance-sheet changes in the detailed schedules.

The full read

Sattva Sukun Lifecare has filed its audited results for Q4 and the full year ended March 31, 2026. The auditor's report is unmodified. More consequentially for governance, the company confirmed it deployed its ₹19.16 crore rights-issue proceeds without any deviation from the stated objects. For a company with a ₹29 crore market cap, this is compliance housekeeping. The numbers are now available for fundamental analysis, but the filing offers no new narrative. The clean audit and deviation clearance remove potential questions, not create answers.

Primary source: BSE · NSE

Sattva Sukun files routine FY26 results and rights-issue utilisation report

Tipsheet Editorial — Thu, 04 Jun 2026 20:31:51 GMT

The board signed off on audited results and a statement confirming rights-issue proceeds were spent as planned. No surprises.

What’s new

Board approved audited standalone and consolidated financial results for Q4 and FY26.
Auditor reports were presented to the board.
A deviation statement on the utilisation of rights-issue proceeds was filed, showing funds were used as intended.

Why it matters

This is the standard annual update from a tiny company. The new data gives fundamental analysts the latest earnings and balance-sheet snapshot, but the filing contains no guidance, profit warning, or strategic shift. For a ₹29 crore market-cap stock, any price movement will be about the numbers themselves.

What we’re watching

The actual FY26 profit and loss figures once they are parsed by the market.
Any significant movement in the stock price post-results, though the nano-cap size suggests volatility.
The next quarterly update to see if the trend continues.

The full read

Sattva Sukun Lifecare's board signed off on its audited FY26 results. For a company with a ₹29 crore market cap, this is the main annual disclosure. It landed without drama. The filing bundles the quarterly and full-year numbers, auditor sign-offs, and a statement confirming its rights-issue proceeds were spent as planned. There is no guidance, no warning, and no strategic pivot. The only new information is the financial data itself. For a stock this small, the reaction will be in the trading, not the filing.

Primary source: BSE · NSE